VIP

InvestigationalExtensive Research

Also known as: Vasoactive Intestinal Peptide · Aviptadil

A neuropeptide with potent anti-inflammatory, immune-modulating, and vasodilatory properties, studied for CIRS, pulmonary conditions, and autoimmune disorders.

Overview

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide with wide-ranging physiological effects including vasodilation, smooth muscle relaxation, immune modulation, and neuroprotection. VIP is produced throughout the body — in the gut, brain, pancreas, and immune cells — and acts through VPAC1 and VPAC2 receptors. In health optimization, VIP has gained significant attention for its role in treating Chronic Inflammatory Response Syndrome (CIRS), a condition caused by biotoxin exposure (mold, Lyme disease). VIP reduces inflammation, restores regulatory T-cell function, normalizes inflammatory markers (TGF-beta, MMP-9, MSH), and improves symptoms in CIRS patients.

It is also being studied for pulmonary arterial hypertension, ARDS (including COVID-19-related), and various autoimmune conditions. VIP's ability to shift the immune system from Th1/Th17 (pro-inflammatory) toward Th2/Treg (anti-inflammatory/regulatory) makes it a powerful tool for immune modulation.

Mechanism of Action

Binds to VPAC1 and VPAC2 G-protein coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP. Suppresses pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12), promotes anti-inflammatory cytokines (IL-10), shifts T-cell balance toward Treg, causes vasodilation via smooth muscle relaxation, and provides neuroprotection.

Key Benefits

Potent anti-inflammatory effects
CIRS symptom improvement
Immune system regulation
Vasodilation and blood flow improvement
Neuroprotective properties
Pulmonary function support

Potential Side Effects

Diarrhea (most common)
Facial flushing
Hypotension
Nasal congestion (intranasal)
Headache

Common Stacks

This peptide is commonly combined with the following compounds for synergistic effects:

BPC-157KPVThymosin Alpha 1LL-37

Known Interactions

The following interactions have been documented for VIP. Always consult a healthcare professional before combining compounds.

Synergistic (1)

KPVSynergistic

VIP (Vasoactive Intestinal Peptide) regulates immune tolerance and reduces neuroinflammation while KPV suppresses NF-kB. Powerful anti-inflammatory combination.

View all compound interactions

Scientific References

Quick Reference

Typical Dose

50mcg-100mcg

Frequency

1-2x daily AM and PM

Route

Subcutaneous injection or intranasal

Half-Life

~1-2 minutes (IV) / longer with subcutaneous

Cycle Length

4-12 weeks; daily use, followed by 4-8 weeks recovery

FDA Status

Investigational — Aviptadil (IV VIP) has FDA Fast Track designation for ARDS. Intranasal/injectable VIP not FDA approved for CIRS.

Need to calculate dosing?

Use our reconstitution calculator to determine exact syringe measurements.

Open Calculator

This information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.

Related Peptides in Immune & Antimicrobial